Chemo, Immunotherapy Combo May Help Fight Liver Cancer, Study Says
Combining the chemotherapy agent Sutent (sunitinib) and immunotherapy may be a promising strategy to fight hepatocellular carcinoma, the most common type of liver cancer, according…
Liver cancer
Tivantinib Provides No Survival Benefit in Hepatocellular Carcinoma Patients, Phase 3 Study Shows
Tivantinib, an experimental oral inhibitor of the MET receptor, is not better than best supportive care in patients with inoperable hepatocellular carcinoma (HCC) who are intolerant or…
Recent Posts
- Livdelzi approved in UK as PBC treatment for certain adults
- Bylvay, Kayfanda in EU, safely treats PFIC: Real-world study
- How I’m learning to cope with challenges as a rare disease parent
- IBAT inhibitors have potential to boost life quality for patients
- Trial of HBV treatment candidate now enrolling final patient group